兔模型股腘病变中三种紫杉醇涂层球囊的生物药物效应与远端颗粒栓塞差异
在18只兔健康降主动脉内分别扩张三种紫杉醇涂层球囊(DCB),28天后评估组织病理与紫杉醇浓度。Ranger病变处紫杉醇浓度最高、中膜平滑肌严重丢失角度最大,但远端骨骼肌浓度与下游效应动脉数低于IN.PACT,Lutonix远端栓塞最低。作者认为Ranger紫杉醇效应最强、远端栓塞第二好,是外周动脉疾病可选方案之一,但需更大样本临床头对头比较。
要点
- Ranger病变处紫杉醇浓度1089 pmol/mg,高于IN.PACT的638与Lutonix的25(p<0.0001)。
- Ranger中膜平滑肌严重丢失角度12.8度,大于IN.PACT的1.4度与Lutonix的0.8度。
- Lutonix远端骨骼肌紫杉醇浓度12 pmol/mg最低,IN.PACT的42 pmol/mg最高(p<0.0001)。
核心结论
- 作者认为三种DCB中Ranger的紫杉醇效应最强、远端颗粒栓塞效应第二好,是外周动脉疾病患者的良好治疗选择。
- 作者指出需更大样本的临床头对头比较来探索哪种DCB最有效且安全。
研究设计与样本
- 在18只兔的健康降主动脉内扩张三种紫杉醇涂层球囊(高剂量IN.PACT Admiral与低剂量Ranger、Lutonix),术后28天处死。
- 对处理的降主动脉与远端骨骼肌行组织病理学评估并测量紫杉醇浓度。
主要发现
- 病变处紫杉醇浓度Ranger 1089(745-2170)pmol/mg vs IN.PACT 638(160-2075)pmol/mg vs Lutonix 25(10-304)pmol/mg,p<0.0001。
- 中膜平滑肌细胞严重丢失角度Ranger 12.8(8.0-20.4)度 vs IN.PACT 1.4(1.2-5.2)度 vs Lutonix 0.8(0.5-2.5)度,Ranger vs IN.PACT p=0.007、Ranger vs Lutonix p=0.002。
- 远端骨骼肌紫杉醇浓度Lutonix 12(1-58)pmol/mg vs Ranger 15(13-21)pmol/mg vs IN.PACT 42(19-108)pmol/mg,p<0.0001。
- 下游DCB效应动脉数Ranger 3(3-4)vs IN.PACT 4(3-7)vs Lutonix 2(1-2),与组织紫杉醇浓度一致。
临床怎么用
- 作者认为Ranger在三种DCB中紫杉醇效应最强、远端颗粒栓塞效应第二好,可作为间歇性跛行与慢性肢体威胁性缺血患者的良好治疗。
- 作者指出需更大样本临床头对头比较以确定最有效且安全的DCB。
局限性
- 作者指出需更大样本的临床头对头比较来探索哪种DCB最有效且安全。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A recent meta-analysis of randomized control trials demonstrated a significantly higher risk of major amputation in patients treated with drug-coated balloons (DCBs) compared with standard treatment, especially in high-dose paclitaxel-coated DCBs. Distal particulate embolization after DCB use was considered a potential cause of the higher incidence of major amputation. The current study aimed to histologically and biologically compare biologic drug effect and distal particulate embolization in 3 DCBs (a high-dose paclitaxel-coated DCB [IN.PACT Admiral] and 2 low-dose paclitaxel-coated DCBs [Ranger and Lutonix]). METHODS AND RESULTS: The DCBs were inflated in the healthy descending aortas of 18 rabbits, followed by euthanasia 28 days after the procedure. The treated descending aorta and distal skeletal muscles were histopathologically evaluated, and paclitaxel concentrations were measured. The paclitaxel concentration of the treated lesion was highest for Ranger, followed by IN.PACT and Lutonix (Ranger vs IN.PACT vs Lutonix: 1089 [745-2170] pmol/mg vs 638 [160-2075] pmol/mg vs 25 [10-304] pmol/mg, respectively; p<0.0001). In the histopathological evaluation, the angle of severe medial smooth muscle cell loss was largest for Ranger followed by IN.PACT and Lutonix (12.8 [8.0-20.4] degree vs 1.4 [1.2-5.2] degree vs 0.8 [0.5-2.5] degree, respectively), with significant differences for Ranger vs IN.PACT (p=0.007) and Ranger vs Lutonix (p=0.002). However, paclitaxel concentrations of distal skeletal muscles were lowest for Lutonix, followed by Ranger and IN.PACT (12 [1-58] pmol/mg vs 15 [13-21] pmol/mg vs 42 [19-108] pmol/mg, respectively, p<0.0001). The numbers of arteries with downstream DCB effects were highest for IN.PACT, followed by Ranger and Lutonix (Ranger vs IN.PACT vs Lutonix, 3 [3-4] vs 4 [3-7] vs 2 [1-2], respectively), which was consistent with the measured tissue paclitaxel concentrations. CONCLUSION: These findings suggest that Ranger demonstrates the strongest paclitaxel effect, as well as the second-best effect regarding distal particulate embolization, making it a good treatment option for patients with peripheral artery disease among the 3 DCBs evaluated in the current study. Further clinical head-to-head comparisons with larger numbers of patients are needed to explore which DCB is the most effective and safe treatment option.Clinical Impact:The findings of the current preclinical study suggests that Ranger demonstrates the strongest paclitaxel effect, as well as the second-best effect regarding distal particulate embolization making it a good treatment for patients with intermittent claudication and chronic limb-threatening ischemia.
引用
- Yoshikawa M, Torii S, Aihara K, et al. Differences in Biologic Drug Effects and Distal Particulate Embolization in Three Paclitaxel-Coated Balloons for Femoropopliteal Lesions in a Rabbit Model. J Endovasc Ther. 2023. PMID: 36951275. doi:10.1177/15266028231161215
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。